Takeda’s general manager for Turkey, Şeyda Atadan Memiş, reflects on the Japanese giant’s ambitions in Turkey at a pivotal moment when the Shire integration has been completed. Atadan discusses how the organization has seized on Takeda’s revamped portfolio, focusing on rare diseases, haematology, immunology, gastroenterology, and oncology, to move up the ranking and become a top eight company among multinationals. In addition, the Turkish executive talks about Takeda-ism and the goal of bringing better health for a brighter future.
The objective [for Turkey] now should be to implement policies in areas like rare diseases so that we can expedite access to innovative medicines for diseases with high unmet medical needs
